What's Happening?
Novo Nordisk, a leading pharmaceutical company, is set to lose its exclusive hold on the diabetes drug semaglutide, marketed as Ozempic, as its patent expires in several major global markets. This development will allow generic versions of the drug to enter
markets in countries such as India, China, Canada, Brazil, Turkey, and South Africa. These regions collectively represent about 40% of the global population, including hundreds of millions of individuals with obesity or diabetes. The introduction of generics is expected to significantly reduce the cost of the drug, making it more accessible to a broader population. In India, for instance, analysts predict that around 50 generic versions could soon be available, potentially reducing monthly costs to approximately $15, compared to the current prices that can reach several hundred dollars.
Why It's Important?
The expiration of the patent on semaglutide is significant as it democratizes access to a crucial medication that has been largely restricted to wealthier nations and individuals. The availability of cheaper generics could enable national health systems in middle-income countries to provide broader coverage for diabetes and potentially for preventing cardiovascular diseases. This shift poses a challenge to Novo Nordisk, which is already facing competition from Eli Lilly's similar drugs and compounded versions in the US. The company may need to reposition its original product as a premium brand in markets where generics become available. Meanwhile, in the US and Europe, patent protections will delay the introduction of generics until the early 2030s, potentially costing patients and taxpayers billions.
What's Next?
As generic versions of semaglutide become available in various countries, Novo Nordisk may intensify its efforts to maintain market share by reducing prices and enhancing its product offerings. The company is likely to continue legal battles to protect its patents in regions where it still holds exclusivity. Additionally, the introduction of generics could prompt healthcare systems in affected countries to reassess their drug coverage policies, potentially expanding access to diabetes and cardiovascular treatments. In the US, the delay in generic availability may lead to increased advocacy for policy changes to expedite access to affordable medications.
